Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

	PATIENT:
	Name:
	NHI:
ccal (A, C, Y and W-135) conjugate vaccine	
Children under 12 months of age (tick boxes where appropriate)	
A maximum of three doses (dependant on age at first dose) fanatomic asplenia, HIV, complement deficiency (acquired or	or patients pre- and post- splenectomy and for patients with functional or inherited), or pre- or post- solid organ transplant
A maximum of three doses (dependant on age at first dose) f	or close contacts of meningococcal cases of any group
A maximum of three doses (dependant on age at first dose) f	or child who has previously had meningococcal disease of any group
A maximum of three doses (dependant on age at first dose) f	or bone marrow transplant patients
	or child pre- and post-immunosuppression*
	Children under 12 months of age (tick boxes where appropriate) A maximum of three doses (dependant on age at first dose) if anatomic asplenia, HIV, complement deficiency (acquired or A maximum of three doses (dependant on age at first dose) if A maximum of three doses (dependant on age at first dose) if

Note: infants from 6 weeks to less than 6 months of age require a 2+1 schedule, infants from 6 months to less than 12 months of age require a 1+1 schedule. Refer to the Immunisation Handbook for recommended booster schedules with meningococcal ACWY vaccine.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

I confirm that the above details are correct:	
Signed:	Date: